Xylem (XYL) Cash & Equivalents (2010 - 2026)

Xylem's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $808.0 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 23.7% year-over-year to $808.0 million; the TTM figure through Mar 2026 stood at $808.0 million (down 23.7% YoY), while the FY2025 annual figure was $1.5 billion, up 31.94% from the prior year.
• Cash & Equivalents was $808.0 million for Q1 2026 at Xylem, down from $1.5 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.5 billion in Q4 2025 to a low of $705.0 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $1.0 billion across 5 years, with a median of $1.0 billion in 2023.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents plunged 40.56% in 2023, then jumped 43.56% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $944.0 million in 2022, then rose by 7.94% to $1.0 billion in 2023, then advanced by 10.01% to $1.1 billion in 2024, then surged by 31.94% to $1.5 billion in 2025, then tumbled by 45.37% to $808.0 million in 2026.
• The last three Cash & Equivalents figures came in at $808.0 million (Q1 2026), $1.5 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.